|

IN10018 Clinical Trials

5 actively recruiting trials

Also known as: BI 853520, BI853520

Pipeline

Phase 1: 1Phase 2: 1Phase 1/2: 3

Top Sponsors

  • InxMed (Shanghai) Co., Ltd.4
  • Jemincare1

Indications

  • Cancer5
  • Lung Cancer2
  • Ovarian Cancer Recurrent1
  • Small Cell Lung Cancer Extensive Stage1
  • NSCLC (Advanced Non-small Cell Lung Cancer)1

Other5 trials

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
Phase 1
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
Phase 1/2
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Phase 1/2
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Phase 2
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.